Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 3
1999 1
2013 1
2014 2
2015 2
2016 2
2017 1
2020 2
2021 2
2022 3
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.
Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon SS, Kavanagh D, Haller H; 311 Study Group. Rondeau E, et al. Kidney Int. 2020 Jun;97(6):1287-1296. doi: 10.1016/j.kint.2020.01.035. Epub 2020 Mar 6. Kidney Int. 2020. PMID: 32299680 Free article. Clinical Trial.
Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults.
Barbour T, Scully M, Ariceta G, Cataland S, Garlo K, Heyne N, Luque Y, Menne J, Miyakawa Y, Yoon SS, Kavanagh D; 311 Study Group Members. Barbour T, et al. Kidney Int Rep. 2021 Mar 24;6(6):1603-1613. doi: 10.1016/j.ekir.2021.03.884. eCollection 2021 Jun. Kidney Int Rep. 2021. PMID: 34169200 Free PMC article.
An ontology-based approach for modelling and querying Alzheimer's disease data.
Taglino F, Cumbo F, Antognoli G, Arisi I, D'Onofrio M, Perazzoni F, Voyat R, Fiscon G, Conte F, Canevelli M, Bruno G, Mecocci P, Bertolazzi P; Alzheimer’s Disease Neuroimaging Initiative. Taglino F, et al. Among authors: antognoli g. BMC Med Inform Decis Mak. 2023 Aug 8;23(1):153. doi: 10.1186/s12911-023-02211-6. BMC Med Inform Decis Mak. 2023. PMID: 37553569 Free PMC article.
Corrigendum to "Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment." Kidney Int. 2020;97:1287-1296.
Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon SS, Kavanagh D, Haller H; 311 Study Group. Rondeau E, et al. Kidney Int. 2021 May;99(5):1244. doi: 10.1016/j.kint.2021.03.008. Kidney Int. 2021. PMID: 33892867 No abstract available.
De novo collapsing glomerulopathy after kidney transplantation: Description of two cases.
Cutruzzulà R, Laudicina S, Bagalà A, Caroti L, Bartiromo M, Gianassi I, Moscarelli L, Di Maria L, Larti A, Allinovi M, Antognoli G, Cirami CL. Cutruzzulà R, et al. Among authors: antognoli g. Clin Nephrol Case Stud. 2023 Apr 19;11:66-71. doi: 10.5414/CNCS110887. eCollection 2023. Clin Nephrol Case Stud. 2023. PMID: 37114160 Free PMC article.
Erratum to "Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D, Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment" Kidney Int. 2020;97:1287-1296.
Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon SS, Kavanagh D, Haller H; 311 Study Group. Rondeau E, et al. Kidney Int. 2020 Dec;98(6):1621. doi: 10.1016/j.kint.2020.11.001. Kidney Int. 2020. PMID: 33276869 Free article. No abstract available.
Development of 2,2-dimethylchromanol cysteinyl LT1 receptor antagonists.
Chambers RJ, Antognoli GW, Cheng JB, Kuperman AV, Liston TC, Marfat A, Owens BS, Pillar JS, Shirley JT, Watson JW. Chambers RJ, et al. Among authors: antognoli gw. Bioorg Med Chem Lett. 1998 Dec 15;8(24):3577-82. doi: 10.1016/s0960-894x(98)00654-4. Bioorg Med Chem Lett. 1998. PMID: 9934474
21 results